no. | Name | Type | Quality | American HIV treatment guidelines | European AIDS guidelines | Reference |
---|---|---|---|---|---|---|
 | A. Baseline evaluation |  |  |  |  |  |
1 | CD4 cell count measurement | P | S | + | + | |
2 | Appropriate viral load test timing | P | S | + | + | |
3 | Renal basic assessment (Creatinine, Blood urea nitrogen, ) | P | G | + | + | |
4 | Complete blood count | P | G | + | + | |
5 | Chemistry analysis (Serum LDH , Sodium, Venous bicarbonate, Hypoxemia ratio, Serum albumin) | P | G | + | - | [24] |
6 | Proportion of patients with CD4 count greater than 200 cells/ul | O | S | + | + | |
7 | Bilirubin | O | G | + | + | [24] |
8 | Admission body mass index | O | G | - | + | [24] |
9 | Ask about loss of appetite | P | G | - | + | [24] |
10 | Monitor patient’s weight | P | G | - | + | |
11 | CNS change | O | G | - | + | [21] |
12 | Complicated cough | O | G | - | - | [24] |
13 | Diarrhea | O | G | - | - | [24] |
14 | Heart rate | O | G | - | + | [24] |
15 | Rales | O | G | - | - | [20] |
16 | Respiratory rate | O | G | - | - | [21] |
17 | Lung examination | P | G | + | + | [24] |
18 | ECG performed in patients on methadone | P | S | - | + | [31] |
19 | Cardiovascular risk assessment | P | G | - | + | [31] |
 | B. Screening |  |  |  |  |  |
20 | Cervical cancer screening (basis and follow up) | P | G | + | + | |
21 | Hepatitis C screening (basis and follow up) | P | G | + | + | |
22 | Hepatitis B testing ever (basis and follow up) | P | G | + | + | |
23 | Tuberculosis screening | P | G | + | + | |
24 | Gonorrhea/chlamydia screening (at least once) | P | S | - | + | |
25 | Syphilis screening (annually) | P | S | - | + | |
26 | Injection drug use screening (annually) | P | G | - | + | |
27 | High-risk sexual behavior screening (annually) | P | G | - | + | |
28 | Papanicolau test in last year (for women only) | P | G | - | + | |
 | C. Immunization |  |  |  |  |  |
29 | Pneumococcal vaccine in previous 6 months if CD4 >200 | P | G | - | + | |
30 | Influenza vaccination (annually) | P | G | - | + | |
31 | Hepatitis B vaccination first dose received (if appropriate) | P | G | + | + | |
32 | Hepatitis A vaccination | P | G | + | + | |
 | D. Prophylaxis (patients with <200 lymphocyte CD4) |  |  |  |  |  |
33 | MAC prophylaxis | P | G | - | - | |
34 | PCP (pneumocystis jiroveci pneumonia) prophylaxis | P | G | - | - | |
35 | Toxoplasmosis prophylaxis | P | G | - | - | |
36 | TB prophylaxis if reactive PPD | P | G | + | - | [25] |
37 | Cryptococcosis prophylaxis for patients with CD4 <100 cells/ul | P | G | - | - | [30] |
 | E. HIV Monitoring |  |  |  |  |  |
38 | Non-detectable HIV viral load at 48 treatment weeks | O | S | + | + | |
39 | Proportion of patients who received their fist-time CD4 count within 2 weeks after first HIV clinic visit | P | S | - | - | |
40 | Proportion of patients eligible for ART who are currently on ART | P | S | + | + | [29] |
41 | Proportion of patients on ART for whom adherence is measured on last three visits | P | S | - | - | |
42 | Proportion of patients on NVP who had LFT at least once within 1 month after initiation of NVP-based ART | P | S | - | - | [29] |
43 | Proportion of patients with previous ARV regimen change for whom reason for change in regime is documented | P | S | + | + | |
44 | Proportion of patients on ARV with at least 95% (good) reported adherence on last visit | O | S | + | + | |
45 | Achieving maximal viral control if prescribed ART | O | S | + | + | [27] |
46 | Achieving maximal viral control if prescribed ART or treatment plan documentation if maximal viral control not achieved. | O | S | + | + | [27] |
47 | proportion of patients with continued care | P | G | + | + | |
48 | Visits in three quarters | P | G | + | - | |
49 | HIV counseling and test offered | P | S | + | + | |
50 | Length of stay in hospital | P | G | - | - | [20] |
51 | Loss of follow up | P | G | + | - | |
52 | Percent HIV/AIDS hospital mortality | O | S | - | - | [20] |
53 | HIV prevalence among pregnant women | P | S | + | + | [22] |
 | F. Therapy |  |  |  |  |  |
54 | Appropriately prescribed ART | P | S | + | + | |
55 | Proportion of patients on cotrimoxazole prophylaxis with at least 95% reported adherence on last visit | P | S | - | - | |
56 | Proportion of patients whose CD4 count is <350 cell/ul who are currently on cotrimoxazole prophylactic therapy | P | S | - | - | [29] |
57 | In patients with at most CD4 count <200 cells/microliter Prescribe an antibiotic or admit the patient to the hospital | P | S | - | - | [24] |
58 | Proportions of patients on ART who are started on ART within 2 weeks after clinical eligibility is confirmed | P | S | + | + | [29] |
59 | Proportion of either bedridden or ambulatory patients who have improvement in functional status | O | S | - | + | [29] |
60 | Proportion of HIV-positive clients given treatment for latent TB infection | P | S | + | + | |
61 | Proportion of HIV-positive registered TB patients given ART during TB treatment | P | S | + | + | [22] |
62 | Percent of HIV-positive patients in HIV care or treatment (pre-ART or ART) who started TB treatment | P | S | + | + | |
63 | Patient with HIV receiving Hepatitis C treatment | P | G | + | + | [31] |
64 | Co-management of Tuberculosis and HIV Treatment | P | S | + | + | [22] |
65 | Number of HIV-positive pregnant women who received antiretroviral to reduce risk of mother-to-child-transmission | P | S | + | + | [22] |